SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
VERTEX
(NQNM:VRTX Last Sale: 264.69 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (VRTX : $264.69)
$68,625,804 million Market Cap at Market Close, July 1, 2022
Biomedics SubIndustry up .00% / Health Industry up .00% Today
130 Waverly Street Research Report Earnings Snapshot - Last 01/28/19
Cambridge, MA 02139 Fact Sheet
Phone: (617) 444-6100 Financial Statements
Peer Comparison
Annual Reports

Joshua S. Boger, Founder, Matthew Emmens, Non Ex. Chmn./CEO/Pres., Ian F. Smith, CFO
FDA indicated hepatitis C drug telaprevir proven effective, April 25, 2011. Successful trial of Hepatitis C drug, VX-950, May 2005. Working to develop and commercialize novel small molecule drugs that address significant markets with major unmet medical needs, including the treatment of viral diseases, cancer, auto-immune and inflammatory diseases, and neurological disorders.
Historical Charts    Technical Analysis
No Historical Data available for VRTX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common VRTX $264.69 $264.69 0 .0 $256.01 $265 2,209,478 $256.01 $265 259,268,593
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock #############

Split, Dividend and Symbol Change Information
Date Symbol Transaction Dividend Split New Symbol
23-AUG-00 VRTX Split 2 for 1

A598
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex